NOTICES

NOTICE: EXPANSION OF THE FLORIDA DEMONSTRATION PROJECT ................. 1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

DATED ANNOUNCEMENTS (RFPs AND RFAs)

PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS
DEVELOPED FOR AIDS AND RELATED ILLNESSES (RFP) ...................... 1
National Cancer Institute
Index: CANCER

ALVEOLAR MACROPHAGES AND DEFENSE OF THE LUNG IN AIDS (RFA) ............. 2
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD

ONGOING PROGRAM ANNOUNCEMENTS

MINORITY INVESTIGATOR RESEARCH SUPPLEMENT (PA) ....................... 3
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD
NOTICES

NOTICE: EXPANSION OF THE FLORIDA DEMONSTRATION PROJECT

P.T. 34; K.W. 1014002

National Institutes of Health

The Office of Management and Budget (OMB) has approved the expansion of the current Florida Demonstration Project to reduce unnecessary administrative burden on sponsored research. This project has enjoyed considerable success among ten universities in the State of Florida and five Federal agencies, the National Institutes of Health, the National Science Foundation, the Department of Energy, the Office of Naval Research, and the U.S. Department of Agriculture.

The OMB approval authorizes agencies to make routine use of the most successful Florida Demonstration Project procedures in grant supported research. Administrative features such as post-award prior approvals, automatic carryover of funds, no-cost extensions, and pre-award costs will be implemented as standard provisions on a significant number of research grant mechanisms.

The OMB approval to expand the Demonstration permits the selection of additional institutions nationwide, as well as encourages the participation of additional Federal agencies. A Notice in the Federal Register, (beginning page 20,6971, June 6, 1988), explains the scope of Phase II of the Demonstration and describes the process for selecting additional institutions. Phase II will have the following basic purposes for both research grants and contracts:

To define and test further certain features of the Florida Demonstration Project.

To identify and test or review new features.

To serve as the basis for the continued development of a model policy for the administration of all fundamental research and related awards.

To serve as a catalyst for awardee organizations and state government participation in reducing unnecessary or redundant internal and state systems administrative burden.

To examine the potential effects of administrative requirements on research productivity and/or costs.

The ten institutions in the State of Florida may elect to continue to participate in Phase II as well as five other institutions that have participated in ancillary studies. An additional ten to fifteen participants may be selected on a nationally competitive basis as outlined in the Federal register. Participation is limited for the sake of demonstration and evaluation. Phase II of the Demonstration will begin on October 1, 1988. This Demonstration will result in further improvements in sponsored programs which will enhance research productivity and cost effectiveness.

For further information, see the Notice in the Federal Register, June 6, 1988.

DATED ANNOUNCEMENTS (RFPs AND RFAs)

PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS DEVELOPED FOR AIDS AND RELATED ILLNESSES

RFP AVAILABLE: NCI-CM-97574-29

P.T. 34; K.W. 0710100, 1007009, 0715120, 0740020

National Cancer Institute

The Developmental Therapeutics Program of the National Cancer Institute is seeking organizations to carry out Pharmacology and Toxicology studies, the data from which must be suitable for filing with the Food and Drug Administration as part of Investigational New Drug Applications. The organizations should have the facilities and staff to carry out such studies and the management expertise to analyze and evaluate the data.

Vol. 17, No. 21, June 24, 1988 - Page 1
As a minimum requirement, the contractors must perform all toxicology studies in accord with the FDA's current Good Laboratory Practice Regulations (GLPs). Multiple contracts will be awarded and each will be administered on a task-managed basis. Task orders will be issued under the "funded cost-reimbursement level-of-effort" contracts resulting from this solicitation. Assignments are estimated to involve four to six chemical agents annually. The objectives of the task orders to be issued are:

Validation of analytical methodology to quantitate drug plasma levels in laboratory animals and to measure levels in rodents and dogs treated with the agent under study.

Determination of bioavailability of drug after parenteral and/or oral administration.

Assessment of acute and subacute toxicity in rodents and dogs.

The principal investigator should have a doctoral degree in pharmacology/toxicology plus at least three years of experience in directing, implementing and evaluating drug toxicity studies in experimental animals. The pathologist and analytical chemist should likewise have credentials which illustrate their competence and accomplishments in serving as critical team members in the conduct of such studies.

The government anticipates three awards on an incrementally funded basis. Each increment will be for one year and the total contract will be awarded for a three-year period on or about April 30, 1989.

It is anticipated that contracts to be awarded will cover a period of three (3) years and will be incrementally funded. The solicitation represents a recompetition of work done under contracts currently held by Battelle Memorial Institute, Hazleton Laboratories America, and Midwest Research Institute. All responsible sources may submit a proposal which will be considered by the National Cancer Institute.

This is not a Request for Proposal (RFP). It is anticipated that RFP number NCI-CM-97574-29 for the above describe work will be available to interested offerors on or about June 24, 1988, with a closing date for receipt of proposals on August 9, 1988. Copies of the RFP may be obtained by written request to:

Clyde Williams
Contracting Officer
Treatment Contracts Section
Research Contracts Branch
National Cancer Institute, NIH
Blair Building, Room 224
Bethesda, Maryland 20892
Telephone: (301) 427-8737

ALVEOLAR MACROPHAGES AND DEFENSE OF THE LUNG IN AIDS

RFA AVAILABLE: 88-HL-15-L

P.T. 34; K.W. 0715120, 0715125, 0715165, 0710070

National Heart, Lung, and Blood Institute

Application Receipt Date: January 16, 1989

The Interstitial Lung Diseases Branch of the Division of Lung Diseases, National Heart, Lung, and Blood Institute (NHLBI) announces the availability of a Request for Applications (RFA) on the above subject. Copies of the RFA are currently available from staff of the NHLBI.

This program will support basic research on the effects of human immunodeficiency virus infection on alveolar macrophages and on immune defenses in the lung. It is expected that research applications will encompass a variety of approaches and require expertise from a wide range of disciplines including biochemistry, immunology, infectious diseases, molecular biology, pulmonary cell biology, pulmonary medicine and virology.

It is anticipated that six grants will be awarded under this program. The specific amount to be funded, however, will depend on the merit and scope of the applications received and the availability of funds.
A letter of intent is requested by December 1, 1988, and the deadline for receipt of applications is January 16, 1989. The earliest award date for successful applications will be in July 1989. Awards will be made to foreign institutions only for research of very unusual merit, need, and promise. Request for copies of this RFA should be addressed to:

Anthony R. Kalica, Ph.D.
Chief, Interstitial Lung Diseases Branch
Division of Lung Diseases, NHLBI
Westwood Building, Room 6A09
Bethesda, Maryland 20892
Telephone: (301) 496-7034

ONGOING PROGRAM ANNOUNCEMENTS

MINORITY INVESTIGATOR RESEARCH SUPPLEMENT

P.T. 34, FF; K.W. 0710030, 0705015, 0715040, 0715165, 0785070

National Heart, Lung, and Blood Institute

INTRODUCTION

The purpose of this announcement is to encourage minority investigators to pursue careers in heart, lung, or blood research by providing supplemental funds to ongoing research grants supported by NHLBI.

DESCRIPTION

The National Heart, Lung, and Blood Institute (NHLBI) will provide support for members of ethnic minorities underrepresented in biomedical or behavioral research through the Minority Investigator Research Supplement program. This supplement addresses the recruitment of eligible individuals from the full spectrum of ethnic minorities, but with a special emphasis on Blacks, Hispanics, and Native Americans.

Principal investigators who are supported by NHLBI research grants (including R01s, R10s, R18s, R37s, P01s, P50s, P60s and U01s) and who are interested in including underrepresented minority investigators in ongoing research may submit a request for an administrative supplement for this purpose.

ELIGIBILITY

Any principal investigator with an active R01, R10, R18, R37, P01, P50, P60, or U01 grant from NHLBI that has a minimum of two years of research support remaining at the time of a supplemental award is eligible to submit a request for an administrative supplement for the purpose of recruiting a minority investigator to work on the research grant.

A. Minority Investigator - A minority investigator is defined as an individual from an ethnic minority underrepresented in biomedical or behavioral sciences. The minority investigator may be affiliated with the applicant institution or with another nearby institution. The program is intended for the M.D. or Ph.D. who is generally at the junior faculty level, instructor or assistant professor, with at least one year postdoctoral research experience, but who has not received previous funding from NIH as an independent investigator. The minority investigator must be a U.S. citizen, a noncitizen national or permanent resident of the U.S. at the time of application, and must make at least a two year commitment to spend a minimum of 30 percent time on research supported by the parent grant. This supplement is not intended to support summer-only research.

B. Research Experience - The proposed research experience for the minority investigator must be part of the ongoing research of the parent grant. When an award is issued, there should be at least two years of research support remaining on the parent grant. As part of this research experience the minority investigator should have the opportunity to interact with investigators on the parent grant, should be able to contribute intellectually to the research, and should have the opportunity to enhance his/her research skills.

PROVISIONS

In order to receive a Minority Investigator Research Supplement there must be, at the time of the supplemental award, a minimum of two years future support remaining on the parent grant. In the first budget period, funds will be
provided as an administrative supplement to the ongoing research grant. In future budget periods, funds for the minority supplement will be included in the award to the parent grant. Each annual supplemental budget should not exceed $30,000 in direct costs, limited to salary, supplies, and travel, and may not include equipment. The continuation of support for the minority supplement in subsequent years of the grant will depend on a satisfactory review of progress made, research proposed for the next budget period, and the budget. A separate minority supplement progress report and budget page is to be submitted as part of the noncompeting continuation application of the principal investigator. Funding for the supplement always is contingent on funding of the parent grant, and cannot extend beyond the project period of the parent grant. Supplemental awards under this program are for the sole purpose of supporting the research experience of the minority investigator. A minority investigator may receive support under this program on only one grant. The support should be for a minimum of two years duration, and each parent grant can have only one minority investigator at a time. Funds are not transferable to another minority investigator. Simultaneous or overlapping Minority Investigator Research Supplements will not be considered.

The funding of this administrative supplement does not preclude the subsequent submission of applications for career development awards (K series) or investigator-initiated research grants by the minority investigator, or receipt of research support. A minority investigator who previously received a K series award, or an investigator-initiated research project grant from NIH is not eligible to apply for this award.

REVIEW CRITERIA

The research training committees composed of staff from the heart, lung, and blood programs will review requests for supplemental support under this announcement using the following criteria:

- Prior research training and experience of the minority investigator,
- Plans for the proposed research experience in the supplemental request and its relationship to the parent grant, and
- Assurance from the principal investigator that the experience will enhance the research potential and skills of the minority investigator.

APPLICATION PROCEDURES

The principal investigator of the parent grant should submit a request for supplemental funds directly to the NHLBI program division that supports the parent grant. The request should include the following: 1) a letter with the title and grant number of the parent grant and a statement that this is a request for a Minority Investigator Research Supplement; 2) a brief 3-4 page description of the proposed research experience and how it will enhance the capabilities and foster the independent research career of the minority investigator; 3) a statement from the minority investigator outlining research objectives and career goals; 4) a biographical sketch of the minority investigator that includes social security number, a list of publications, and other evidence of scientific achievement; 5) a proposed budget for the research experience on the first year and future years budget pages from Grant Application Form PHS 398; and 6) documentation, if applicable, that the proposed research experience was approved by the animal welfare committee or human subjects institutional review board of the grantee institution. The request must be signed by the principal investigator and the appropriate institutional business official. If the minority investigator is not an employee of the grantee institution, the request also must be accompanied by an appropriately signed letter from the institution of the minority investigator indicating that participation at the stated level of effort is approved.

Requests may be submitted at any time.

The original and four (4) copies of the request should be sent to the NHLBI program division that supports the parent grant. Division representatives are:
Dr. George A. Hayden  
Research Training and Development Branch  
Division of Heart and Vascular Diseases  
National Heart, Lung, and Blood Institute  
Federal Building, Room 3C01  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-1724

or

Dr. Joan M. Wolle  
Prevention, Education, and Research Training Branch  
Division of Lung Diseases  
National Heart, Lung, and Blood Institute  
Westwood Building, Room 640  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7668

or

Dr. Christine Parker  
Program Planning and Prevention Branch  
Division of Blood Diseases and Resources  
National Heart, Lung, and Blood Institute  
Federal Building, Room 520  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-4186

or

Dr. Katrina W. Johnson  
Prevention and Demonstration Research Branch  
Division of Epidemiology and Clinical Applications  
National Heart, Lung, and Blood Institute  
Federal Building, Room 5C10B  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-3503

The programs of the National Heart, Lung, and Blood Institute are identified in Catalog of Federal Domestic Assistance, number 13.837, 13.838, and 13.839. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.